San Antonio Breast Cancer Symposium 2011

In this review:
Zoledronic acid improves breast cancer survival
Early zoledronic acid: long-term benefits
Brachytherapy vs whole-breast irradiation
Genome sequencing in triple-negative breast cancer
Axillary dissection challenged for early breast cancer
Everolimus extends PFS in ER+HER2- women
Lapatinib in HER2+ stage I-IIIc breast cancer
Gene test predicts DCIS recurrence risk
Pertuzumab promising in HER2+ breast cancer
Predictors of early treatment discontinuation

Download PDF Subscribe